Showing results (1451-1460 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|February 1, 2021
The Excess Costs of Depression and the Influence of Sociodemographic and Socioeconomic Factors: Results from the German Health Interview and Examination Survey for Adults (DEGS)Hannah König, Alexander Rommel, Julia Thom, et al.Pharmacoeconomics|November 29, 2021
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence ModelsMin Huang, Scott Ramsey, Weiguang Xue, et al.Pharmacoeconomics|November 1, 2022
An EQ-5D-Y-3L Value Set for BelgiumSarah Dewilde, Bram Roudijk, Nafthali H Tollenaar, et al.Pharmacoeconomics|May 16, 2019
Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with HyperkalemiaMark Bounthavong, Javed Butler, Chantal M Dolan, et al.Pharmacoeconomics|April 24, 2019
Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature ReviewNikolaos Maniadakis, Evgenia KonstantakopoulouPharmacoeconomics|October 18, 2018
Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalTosin Lambe, Rui Duarte, James Mahon, et al.Pharmacoeconomics|October 18, 2021
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)Noman Paracha, Pollyanna Hudson, Stephen Mitchell, et al.Pharmacoeconomics|April 12, 2019
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and NeckKim Cocks, Marta Contente, Sarah Simpson, et al.Pharmacoeconomics|October 29, 2021
Future Offspring Costs in Economic EvaluationEvelyn Verbeke, Jeroen LuytenPharmacoeconomics|September 28, 2021
Biased Survival Predictions When Appraising Health Technologies in Heterogeneous PopulationsDaniel Gallacher, Peter Kimani, Nigel StallardPageof 336